Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Cellectar Biosciences has initiated the Phase 1b clinical trial for CLR 125, an Auger-emitting radioconjugate designed to treat relapsed or refractory triple negative breast cancer (TNBC). This trial marks a key milestone in developing targeted therapies for TNBC, a subtype with limited treatment options. CLR 125 leverages the company's proprietary…